IL1B and neoplasm: Other in vivo evidence showed that administration of Anakinra for 3-days before or 7 days after intra-venous injection of DiD-labelled IL-1B overexpressing (MDA-MB-231-IV) cells had no effect on the number of DiD-labelled cells detected in bone, but inhibited proliferation of these cells in the bone, which suggests inhibition of IL-1B may limit tumour cell reactivation [8].